Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related morbidity and mortality in the western world. PDAC. A 5-year overall survival of only 11%, limited treatment options and an incidence on the rise warrant the development of new therapeutic strategies against PDAC. Oncolytic virotherapy (OV) is a promising treatment for immunologically cold tumors, like PDAC. Vesicular Stomatitis Virus (VSV) specifically infects, replicates and lyses cancer cells without harming healthy cells. Infection with VSV mounts a strong anti-tumor immune response, mediated by the immunogenic cell death (ICD) of infected cancer cells. This immune response can be further enhanced by arming oncolytic VSV with the transgene TNFSF14/LIGHT, known to stimulate the recruitment of tumor infiltrating lymphocytes and formation of tertiary lymphoid structures.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
